感染

订阅

MedSci主页 / 所有栏目 / 感染

2019年美国皮肤病学会（AAD）年会：Dupixent（dupilumab）治疗控制不佳的特应性皮炎

2019-03-02 不详 网络

Dupilumab皮肤病特应性皮炎
关注

再生元和赛诺菲公司今天宣布，将于3月1日至5日在华盛顿特区举行的2019年美国皮肤病学会（AAD）年会上展示各种临床和真实世界数据。再生元项目指导副总裁Neil Graham博士说：“我们将在Dupixent的有效性和安全性的既定知识基础上，公布Dupixent治疗近50,000名中度至重度特应性皮炎控制不当的患者的最新数据”。

再生元和赛诺菲公司今天宣布，将于3月1日至5日在华盛顿特区举行的2019年美国皮肤病学会（AAD）年会上展示各种临床和真实世界数据。再生元项目指导副总裁Neil Graham博士说：“我们将在Dupixent的有效性和安全性的既定知识基础上，公布Dupixent治疗近50,000名中度至重度特应性皮炎控制不当的患者的最新数据”。

再生元和赛诺菲公司将重点介绍Dupixent（dupilumab）治疗成人中重度特应性皮炎患者的III期临床试验（SOLO 1和SOLO 2）的结果，还将介绍对特应性皮炎的疾病和经济负担的真实研究结果。

特应性皮炎（AD）是一种常见的慢性、炎性皮肤病，以瘙痒性湿疹性皮炎为特征。对于大多数患者，治疗该病需要细致的皮肤护理、局部抗炎治疗以及消除加重病情的因素。使用常规治疗无改善的重度AD患者，使用二线治疗如光照疗法或全身性药物治疗可能会有改善。


原始出处：

http://www.firstwordpharma.com/node/1627583#axzz5gyg9tTzO

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1912100, encodeId=8c4f19121002f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 20 19:34:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784832, encodeId=cd0b1e848329a, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6331, encryptionId=00e4633166, topicName=Dupixen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Wed Sep 11 20:34:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826118, encodeId=6e001826118ae, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Jun 03 05:34:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282904, encodeId=240f128290437, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6330, encryptionId=5a67633069, topicName=Dupilumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Mar 04 02:34:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372735, encodeId=511413e273583, content=<a href='/topic/show?id=91a7633258' target=_blank style='color:#2F92EE;'>#Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6332, encryptionId=91a7633258, topicName=Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Mon Mar 04 02:34:00 CST 2019, time=2019-03-04, status=1, ipAttribution=)]
    2019-12-20 snf701207

    #mAb#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1912100, encodeId=8c4f19121002f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 20 19:34:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784832, encodeId=cd0b1e848329a, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6331, encryptionId=00e4633166, topicName=Dupixen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Wed Sep 11 20:34:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826118, encodeId=6e001826118ae, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Jun 03 05:34:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282904, encodeId=240f128290437, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6330, encryptionId=5a67633069, topicName=Dupilumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Mar 04 02:34:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372735, encodeId=511413e273583, content=<a href='/topic/show?id=91a7633258' target=_blank style='color:#2F92EE;'>#Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6332, encryptionId=91a7633258, topicName=Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Mon Mar 04 02:34:00 CST 2019, time=2019-03-04, status=1, ipAttribution=)]
    2019-09-11 yanjie6253_56072842

    #Dupixen#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1912100, encodeId=8c4f19121002f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 20 19:34:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784832, encodeId=cd0b1e848329a, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6331, encryptionId=00e4633166, topicName=Dupixen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Wed Sep 11 20:34:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826118, encodeId=6e001826118ae, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Jun 03 05:34:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282904, encodeId=240f128290437, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6330, encryptionId=5a67633069, topicName=Dupilumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Mar 04 02:34:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372735, encodeId=511413e273583, content=<a href='/topic/show?id=91a7633258' target=_blank style='color:#2F92EE;'>#Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6332, encryptionId=91a7633258, topicName=Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Mon Mar 04 02:34:00 CST 2019, time=2019-03-04, status=1, ipAttribution=)]
    2019-06-03 一叶知秋

    #皮肤病#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1912100, encodeId=8c4f19121002f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 20 19:34:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784832, encodeId=cd0b1e848329a, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6331, encryptionId=00e4633166, topicName=Dupixen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Wed Sep 11 20:34:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826118, encodeId=6e001826118ae, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Jun 03 05:34:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282904, encodeId=240f128290437, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6330, encryptionId=5a67633069, topicName=Dupilumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Mar 04 02:34:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372735, encodeId=511413e273583, content=<a href='/topic/show?id=91a7633258' target=_blank style='color:#2F92EE;'>#Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6332, encryptionId=91a7633258, topicName=Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Mon Mar 04 02:34:00 CST 2019, time=2019-03-04, status=1, ipAttribution=)]
    2019-03-04 zhyy88

    #Dupilumab#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1912100, encodeId=8c4f19121002f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 20 19:34:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784832, encodeId=cd0b1e848329a, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6331, encryptionId=00e4633166, topicName=Dupixen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Wed Sep 11 20:34:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826118, encodeId=6e001826118ae, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Jun 03 05:34:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282904, encodeId=240f128290437, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6330, encryptionId=5a67633069, topicName=Dupilumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Mar 04 02:34:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372735, encodeId=511413e273583, content=<a href='/topic/show?id=91a7633258' target=_blank style='color:#2F92EE;'>#Dupixent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6332, encryptionId=91a7633258, topicName=Dupixent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Mon Mar 04 02:34:00 CST 2019, time=2019-03-04, status=1, ipAttribution=)]
    2019-03-04 yulin2006

    #Dupixent#

    0

相关资讯

NEJM：Dupilumab对皮质激素依赖性重度哮喘患者的疗效显著

研究认为，对于皮质激素依赖性重度哮喘患者，Dupilumab治疗可以减少激素用量，降低恶化率同时增加1s呼气量

2018年 ERS：Dupilumab显著改善中重度哮喘和合并症患者的症状

在2018年欧洲呼吸学会国际大会（ERS）上发表的III期QUEST试验的结果显示，Dupilumab为患有慢性鼻窦炎或鼻息肉病（CRS / NP）的中度至重度哮喘患者提供更好的症状控制，显著改善了与健康相关的生活质量（HRQoL）。

赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果


两项III期试验（SINUS-24和SINUS-52）对患有复发性慢性鼻窦炎和鼻息肉（CRSwNP）的患者进行了详细的研究，这些患者先前接受了手术和/或全身性皮质类固醇治疗。Dupixent（dupilumab）在加入到标准皮质类固醇鼻腔喷雾剂时可改善鼻息肉大小、鼻充血严重程度、慢性鼻窦疾病、嗅觉和咳嗽。

NEJM：两项3期临床试验表明Dupilumab可有效改善特应性皮炎的症状

Dupilumab，是一种抗IL-4受体α的单克隆抗体，抑制IL-4和IL-13信号，2型细胞因子，可能是促使遗传性过敏症或过敏性疾病（如特应性皮炎）发生的重要因素。在两项随机、安慰剂对照、3期临床试验中（SOLO 1和SOLO 2），研究人员招募了局部治疗控制不佳的中重度特应性皮炎成人患者。按1:1:1将患者随机分配至皮下dupilumab（300毫克）或安慰剂，或每隔一周交替使用相同剂量的du

NEJM：Dupilumab治疗中重度不受控制哮喘的疗效显著

研究认为，Dupilumab可降低哮喘患者恶化率，改善肺功能和哮喘症状，特别对于嗜酸性粒细胞基线水平较高人群的疗效更为显著

Lancet：Dupilumab联用糖皮质激素用于中度到重度特应性皮炎

Dupilumab联用糖皮质激素可改善特应性皮炎的症状和体征